Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of AL-4943A in asymptomatic eyes
NCT01698814Phase 3Completed
- Sponsor
- Alcon Inc.
- Start
- Oct 2012
- Primary completion
- Jan 2013
01
Overview
Phase 3, randomised, double-blind trial in allergic conjunctivitis (AC) comparing AL-4943A with AL-4943A Vehicle (2 arms). Primary endpoint: Adverse Events at 6 weeks. Started Oct 2012; status: completed.
02
Drugs
olopatadine
03
Conditions
allergic conjunctivitis (AC)
Beyond the preview
Go deeper on NCT01698814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01698814.